• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • Virtual Data Room (VDR) for Strategic Customized Slide Decks
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

Part 24: Agent Architecture for Corpus Pairing and Training.

Part 24: Agent Architecture for Corpus Pairing and Training.

COM Part 24 is the method for pairing a subject-matter collection with one or more e-Series volumes, and for running that pairing through a coordinated agent system. It is architecture. It is not a second Chart 4.

UPDATED on 10/11/2026

COM Part 24 (Agent Architecture for Corpus Pairing and Training) operationalizes the pairing of the Fifteen Collections documented in Asset EXT-C.4 with selective BioMed e-Series volumes. Already inside via COM Part 13 ($32.5 M). Part 24 itself is Yes in Z. Not a Chart 4 dollar. Not a second bar.

Chart 4 = $650 M remains the single number.

See Slide 16, 2.0 Master Deck, for value statement on the COM Part 24 / Matrix 11 / Boards linkage.

That combination is human-guided, high-provenance, and produces different weights. It is the path to the Frontier Model. It is Yes in Z. Transfer at T1. Fair value = one Z (Cash and Stocks). Not a Chart 4 dollar. Not a second $650 M.

Chart 4 = $650 M remains the single Phase-1 number. Z is the separate fair-value amount for the Category B IP Assets bundle, payable at T1.

UPDATED on 10/11/2026

COM Part 24 (15 Collections operationalizing EXT-C.9.1, paired with expert-selected BioMed volumes): Part 24 is the method that pairs the Collections with relevant volumes for controlled, observable agent runs. It is Yes in Z. Transfers at T1. Fair value = one Z. Not a Chart 4 dollar. It implements the containment and observability harness Satya requires—human-selected pairings, external controls, and auditable boundaries—around any frontier model that runs on the corpus. Not a second bar.

“See COM Part 11 (Satya Nadella, 10 October 2026) for the SI containment and observability principles that these pairings implement.”

The system is one coordinating HyperAgent and five BioMed e-Series Specialized Agents, one for each English e-Series. The knowledge collection is shared. The books are not copied five times. Uploading a volume is retrieval against the source. It is not fine-tuning. Five series agents are added only if the pilot row shows that they improve the answer. The pilot row is the smallest filled row on the grid, not one volume.

Five series Agent specialists are added only if the pilot row shows that they improve the answer. The pilot row is the smallest filled row on the grid, not one volume.

The method has three uses:

Use 1 is the book side.

The 18 English volumes are paired with the 15 Collections of “Articles of Note.” Aviva’s grid fills 123 of 270 cells. No collection is paired with one volume. The floor is 3 volumes. The ceiling is 14. The one-volume start is withdrawn. The pilot is the smallest filled row on that grid. Dr. Williams’s grid is still separate. The inclusive schedule is made only after both grids are in. The pairing is made by a panel of two domain experts and one external referee. Each fills a grid alone. Aviva only, Dr. Williams only, and the inclusive cells are marked in three colors. The inclusive grid is the Use 1 schedule.

Use 2 is the category side.

Each Journal article carries the author’s Category of Research. For an article already in a Collection, the other Journal articles in that same category are fetched and joined into the training. The question is which articles in the assigned category are brought in.

Use 3 is the article-update side.

COM Part 14 is AJAUS. A new or revised Journal article is joined to the Collection it belongs to. EXT-C.9.1 is the map: article ID to collection ID. The article body stays in the Journal valuation.

  • AJAUS does not rewrite a volume.
  • A volume change is Use 1.
  • AJAUS does not fetch the other articles in the author’s category.
  • That fetch is Use 2.

The three Excel sheets are Column H. They are the source record.

Use 2 and Use 3 examples go to Matrix 11. They are utilizations of the same method. They are not a second COM part.

The pairing grids and the worked examples sit on the password-protected child of this page.

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading…

This page has the following sub pages.

  • COM Part 24: Pairing Grids and Worked Examples.

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,037 other subscribers
  • Recent Posts

    • Novartis and Bristol Myers Squibb halt CAR-T trial for autoimmune diseases over patient deaths: a potential issue with cell-based manufacturing September 15, 2026
    • FDA Contemplates Changes in Trial Design, Drug Development, and Use of AI in Clinical Trials September 15, 2026
    • FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
    • Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
    • In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
    • Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
    • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
    • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
    • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
    • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


%d